17β-HSD

Cat. No.

A69059

CAS No.

2770247-67-9

HSD17B13-IN-62-d3

HSD17B13-IN-62-d3 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenases (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This compound is primarily utilized in research related to nonalcoholic fatty liver disease (NAFLD), facilitating the investigation of HSD17B13's role in lipid metabolism and liver function. Its selective inhibition provides valuable insights into the therapeutic potential for addressing metabolic liver disorders.

Cat. No.

A69060

CAS No.

2770246-68-7

HSD17B13-IN-34

HSD17B13-IN-34 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This compound is primarily deployed in research related to nonalcoholic fatty liver disease (NAFLD), facilitating the investigation of HSD17B13's role in lipid metabolism and liver function. Its selective inhibition offers valuable insights into therapeutic strategies targeting dysregulated steroid metabolism in hepatic disorders.

Cat. No.

A69061

CAS No.

2770246-82-5

HSD17B13-IN-56

HSD17B13-IN-56 is a selective inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is crucial for investigating the role of HSD17B13 in various hepatic and metabolic disorders, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its potent inhibition makes it a valuable tool for advancing research in liver pathology and associated cardiovascular conditions.

Cat. No.

A69062

CAS No.

2770246-75-6

HSD17B13-IN-51

HSD17B13-IN-51 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research into liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as drug-induced liver injury (DILI). Its specific targeting of HSD17B13 positions it as a critical tool for investigating metabolic and cardiovascular disease pathways.

Cat. No.

A69063

CAS No.

3012624-88-0

HSD17B13-IN-105

HSD17B13-IN-105 is a selective inhibitor of 17β-hydroxysteroid dehydrogenase 13 (17BHSD13), exhibiting an IC50 value of 0.036 μM and notable selectivity against 17BHSD4 with an IC50 of 31.5 μM. This compound is valuable for research applications targeting liver diseases, particularly non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Its specificity and potent inhibition profile make it a significant tool for studying the biochemical pathways involved in these conditions.

Cat. No.

A69064

CAS No.

2770246-12-1

HSD17B13-IN-48

HSD17B13-IN-48 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its inhibitory action on HSD17B13 makes it a crucial tool for research into the pathophysiology and therapeutic targeting of these conditions.

Cat. No.

A69065

CAS No.

2770247-94-2

HSD17B13-IN-89

HSD17B13-IN-89 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenases (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol. This reagent is primarily utilized in research related to nonalcoholic fatty liver disease (NAFLD), offering valuable insights into the role of HSD17B13 in hepatic metabolism and disease progression. Its specificity and efficacy make it a critical tool for studying the pathophysiology of metabolic disorders.

Cat. No.

A69066

CAS No.

2770247-47-5

HSD17B13-IN-82

HSD17B13-IN-82 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as in metabolic and cardiovascular disorders. Additionally, HSD17B13-IN-82 is useful for studying drug-induced liver injury (DILI) and its underlying mechanisms.

Cat. No.

A69067

CAS No.

1601-18-9

Indomethacin methylester

Synonyms: Indometacin methylester

Indomethacin methylester is a selective inhibitor of AKR1C3, exhibiting an IC50 of 5.67 μM. This compound is particularly relevant for studying its role in prostate cancer research, where it may aid in elucidating the mechanisms underlying tumor progression and therapeutic resistance. Its specificity for AKR1C3 offers potential insights into targeting this enzyme for cancer treatment strategies.

Cat. No.

A69068

CAS No.

2770247-40-8

HSD17B13-IN-71

HSD17B13-IN-71 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for research targeting liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Additionally, HSD17B13-IN-71 can aid in investigations of drug-induced liver injury (DILI), making it a crucial tool in related biological studies.

Cat. No.

A69069

CAS No.

3075100-76-1

HSD17B13-IN-104

HSD17B13-IN-104 is a potent and selective inhibitor of HSD17B13, exhibiting an IC50 of 2.5 nM. This compound effectively modulates hepatic lipid metabolism by targeting the SREBP-1c/FAS signaling pathway, thereby reducing hepatic lipid accumulation. HSD17B13-IN-104 holds potential for advancing research on metabolic dysfunction-associated steatohepatitis and related conditions.

Cat. No.

A69070

CAS No.

2849338-41-4

HSD17B13-IN-95

HSD17B13-IN-95 is a potent inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), with an IC50 value for estradiol of less than 0.1 μM. This compound is useful in the investigation of nonalcoholic fatty liver disease and other metabolic disorders associated with altered steroid hormone metabolism. Its ability to effectively modulate HSD17B13 activity makes it a valuable tool for research into the biological mechanisms underlying liver function and related pathologies.

Cat. No.

A69071

CAS No.

3004661-16-6

HSD17B13-IN-72

HSD17B13-IN-72 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 value of less than 0.1 μM for estradiol. This compound is valuable for studying the role of HSD17B13 in liver diseases and metabolic disorders, facilitating research into potential therapeutic interventions and mechanisms underlying these conditions. Its high specificity makes it an important tool for elucidating the biological pathways associated with steroid metabolism.

Cat. No.

A69072

CAS No.

2770246-37-0

HSD17B13-IN-24

HSD17B13-IN-24 is a potent inhibitor of 17β-Hydroxysteroid dehydrogenases (HSD17B13) with an IC50 value of less than 0.1 μM for estradiol. This compound is primarily utilized in research related to nonalcoholic fatty liver disease (NAFLD), facilitating the understanding of metabolic pathways and potential therapeutic targets in liver disorders. Its high specificity makes it a valuable tool for investigating the role of HSD17B13 in various biological contexts.

Cat. No.

A69073

CAS No.

2770247-58-8

HSD17B13-IN-55

HSD17B13-IN-55 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic and cardiovascular disorders. Additionally, it may support research into drug-induced liver injury (DILI), providing insights into its mechanisms and potential therapeutic interventions.

Cat. No.

A69074

CAS No.

2770247-26-0

HSD17B13-IN-61

HSD17B13-IN-61 is a specific inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is intended for research into liver-related conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI), as well as various metabolic and cardiovascular diseases. Its high potency makes it a valuable tool for investigating the role of HSD17B13 in these disease contexts.

Cat. No.

A69075

CAS No.

2848620-81-3

HSD17B13-IN-90

HSD17B13-IN-90 is a selective inhibitor of 17β-Hydroxysteroid dehydrogenases, specifically targeting HSD17B13, with an IC50 of less than 0.1 μM for estradiol. This compound is employed in research related to nonalcoholic fatty liver disease (NAFLD), providing insights into the role of HSD17B13 in lipid metabolism and liver function. Its potent inhibitory activity makes it a valuable tool for investigating the biological effects of steroid hormone modulation in various pathological contexts.

Cat. No.

A69076

CAS No.

2758802-18-3

HSD17B13-IN-21

HSD17B13-IN-21 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), exhibiting an IC50 of less than 0.1 μM for estradiol and less than 1 μM for leukotriene B3. This compound is significant in the study of nonalcoholic fatty liver diseases (NAFLDs), including nonalcoholic steatohepatitis (NASH). Its application in research could provide insight into the mechanisms underlying liver-related metabolic disorders.

Cat. No.

A69077

CAS No.

2758802-04-7

HSD17B13-IN-12

HSD17B13-IN-12 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for both leukotriene B3 and estradiol. This compound is valuable for studying liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). Its targeted inhibition offers insights into the biochemical pathways associated with these health issues.

Cat. No.

A69078

CAS No.

2770247-49-7

HSD17B13-IN-54

HSD17B13-IN-54 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating the role of HSD17B13 in various pathologies, including liver diseases, metabolic disorders, and cardiovascular conditions such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). Additionally, it serves as a useful tool for studying drug-induced liver injury (DILI).

Cat. No.

A69079

CAS No.

3046195-01-8

PTOTAC HSD17B13 degrader 1

PTOTAC HSD17B13 degrader 1 is a PROTAC designed to selectively target and promote the degradation of 17β-Hydroxysteroid dehydrogenase 13 (HSD17B13). This compound consists of a specific ligand for HSD17B13, a linker based on tert-Butyl 5-bromoisoindoline-2-carboxylate, and a ligand for an E3 ubiquitin ligase, enabling effective ubiquitination and subsequent proteasomal degradation of the target protein. PTOTAC HSD17B13 degrader 1 is a valuable tool for studying HSD17B13 functions and has potential applications in therapeutic development and protein regulation research.

Cat. No.

A69080

CAS No.

2849338-43-6

HSD17B13-IN-96

HSD17B13-IN-96 is a potent inhibitor of 17 β-hydroxysteroid dehydrogenase (HSD17B13), exhibiting an IC50 value for estradiol of less than 0.1 μM. This compound is primarily utilized in research focused on nonalcoholic fatty liver disease (NAFLD) and related metabolic disorders. Its effectiveness in modulating HSD17B13 activity provides valuable insights into the biological pathways involved in liver metabolism and pathology.

Cat. No.

A69081

CAS No.

2770246-39-2

HSD17B13-IN-25

HSD17B13-IN-25 is a specific inhibitor of 17β-Hydroxysteroid dehydrogenase type 13 (HSD17B13), demonstrating an IC50 of less than 0.1 μM for estradiol. This compound plays a significant role in the study of nonalcoholic fatty liver disease (NAFLD) by modulating steroid metabolism and fatty liver progression. Its application in preclinical research facilitates a deeper understanding of HSD17B13's involvement in lipid metabolism and liver pathology.

Cat. No.

A69082

CAS No.

2770246-31-4

HSD17B13-IN-79

HSD17B13-IN-79 is a potent inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13), demonstrating an IC50 value of ≤ 0.1 μM for estradiol. This compound is valuable for investigating liver diseases, metabolic disorders, and cardiovascular conditions, including non-alcoholic fatty liver disease (NAFLD), non-alcoholic steatohepatitis (NASH), and drug-induced liver injury (DILI). HSD17B13-IN-79 serves as an important tool for research aimed at understanding the role of HSD17B13 in these pathological conditions.

Cat. No.

A69083

CAS No.

2848620-83-5

HSD17B13-IN-91

HSD17B13-IN-91 is an inhibitor of hydroxysteroid 17β-dehydrogenase 13 (HSD17B13) with an IC50 value for estradiol ranging between 0.1 μM and 0.5 μM. This compound is utilized in research contexts focusing on liver diseases, including non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH), as well as metabolic disorders and cardiovascular diseases. Additionally, it is relevant for studying drug-induced liver injury (DILI), making it a valuable tool for understanding the role of HSD17B13 in various pathological conditions.